+2,354.1%
AMD vs MRNA
+561.6%
+1,792.5%
-65.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.7% | -2.2% | +6.9% | +4.9% |
| 7D | +2.6% | +5.5% | -2.9% | +2.0% |
| 30D | -0.9% | +158.7% | -159.7% | -17.8% |
| 3M | -8.7% | +182.1% | -190.8% | -25.9% |
| 6M | +136.3% | +151.8% | -15.5% | +95.2% |
| YTD | +123.0% | +393.6% | -270.6% | +63.8% |
| 1Y | +195.2% | +499.5% | -304.3% | +107.9% |
| 3Y | +336.3% | +29.3% | +307.0% | +272.3% |
| 5Y | +334.5% | -65.1% | +399.5% | +316.4% |
| All | +2,354.1% | +561.6% | +1,792.5% | +1,370.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling